IQVIA Holdings Inc. (IQV) Stock
NYSEIQV has an Alpha Score of 44 out of 100 (weak), computed on Nov 3, 2026 from 3 of 4 sub-scores. 8 members of Congress disclosed 25 trades in IQV since 2018: 9 purchases and 16 sales, most recently Kevin Hern (sale, Sep 14, 2026). 7 of the hedge funds AlphaScala tracks reported IQV in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $99.84M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Nov 6, 2026. Its trailing P/E ratio is 32.4 and its net margin 8.1% (key statistics as of Oct 30, 2026).
What is IQV's Alpha Score?
How it works →Alpha Score of 44 reflects weak overall profile with moderate momentum, weak value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 3, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded IQVIA Holdings Inc. (IQV)?
Most recent: Kevin Hern (sale, Sep 14, 2026); records start Mar 9, 2018.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Kevin Hern R-OK · House | 2026-09-14 | sale | $15k – $50k |
| Kevin Hern R-OK · House | 2026-09-08 | sale | $1k – $15k |
| Kevin Hern R-OK · House | 2026-09-03 | sale | $1k – $15k |
| Kevin Hern R-OK · House | 2026-03-16 | sale | $50k – $100k |
| Markwayne Mullin R-OK · Senate | 2025-12-29 | purchase | $15k – $50k |
| John Boozman R-AR · Senate | 2025-10-02 | partial sale | $1k – $15k |
| Rob Bresnahan R-PA · House | 2025-05-15 | sale | $1k – $15k |
| Rob Bresnahan R-PA · House | 2025-04-08 | purchase | $15k – $50k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
See all IQV political trades →Which hedge funds own IQV?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 517K | $99.84M | +93% |
| D.E. Shaw David Shaw | 466K | $90.09M | NEW |
| Point72 Steve Cohen | 279K | $54.00M | NEW |
| Citadel Ken Griffin | 229K | $44.32M | -41% |
| Marshall Wace | 38K | $7.28M | +10363% |
| Bridgewater Associates Ray Dalio | 26K | $5.06M | -44% |
| Blackstone | 2K | $401.9K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are IQVIA Holdings Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 2, 26 | Berkshire James G. | See Remarks | SELL | 2.7K | $697K |
| Aug 3, 26 | Staub W Richard | See Remarks | SELL | 5.5K | $1.3M |
| Jul 31, 26 | Patel Bhavik | See Remarks | SELL | 1.9K | $436K |
| Jul 29, 26 | Bousbib Ari | See Remarks | SELL | 4.5K | $1.1M |
| Jul 29, 26 | Bousbib Ari | See Remarks | SELL | 4.6K | $1.1M |
| Jul 29, 26 | Bousbib Ari | See Remarks | SELL | 44.0K | $10.8M |
| Jul 29, 26 | Bousbib Ari | See Remarks | SELL | 53.2K | $13.0M |
| Jul 29, 26 | Cherofsky Keriann | See Remarks | SELL | 558 | $137K |
| Jul 29, 26 | Sherbet Eric | See Remarks | SELL | 5.0K | $1.2M |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →What are IQV's key statistics?
Key statistics as of Oct 30, 2026
How does IQV's valuation compare with the Healthcare sector?
| Metric | IQV | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 32.4 | 28.8 | 111 |
| Net margin | 8.05% | 4.31% | 164 |
| Return on equity | 21.82% | 5.47% | 185 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 7, 2026). P/E excludes loss-making companies.
IQV price chart
Powered by TradingViewWhat does IQVIA Holdings Inc. do?
IQVIA Holdings Inc. is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. The company operates three primary divisions: Research & Development, which manages all phases of clinical trials from phase I through IV, including clinical pharmacology, regulatory affairs, protocol design, patient recruitment, data management, and biostatistics for pharmaceutical, device, and diagnostic firms; Technology & Analytics, offering aggregated healthcare data, cloud-based customer relationship management software, analytics consulting, and insights from vast non-identified patient records to pharmaceutical companies, providers, payers, and policymakers; and Contract Sales & Medical, providing sales services and patient engagement to healthcare providers. IQVIA Holdings Inc. leverages IQVIA Connected Intelligence™ to deliver agile, evidence-driven solutions that connect data, technology, and expertise, supporting clinical development, commercialization, and healthcare transformation worldwide. Founded in 2016 and headquartered in Durham, North Carolina, it conducts operations in more than 100 countries, playing a pivotal role in accelerating innovations for better patient outcomes in the healthcare ecosystem.